

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

30 December 2024

**VALIRX PLC**

("ValiRx" or the "Company")

**Result of General Meeting**

**Issue of Equity, Warrants and Total Voting Rights**

**Director/PDMR Shareholding**

ValiRx plc (the "Company") (AIM: VAL), announces that, further to the Conditional Fundraising & Notice of General Meeting announcements on 9 December 2024 and 10 December 2024, at its General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.

In aggregate the Company has issued 241,999,999 New Ordinary Shares and 241,999,999 Fundraise Warrants over new ordinary shares.

The Fundraise Warrants are exercisable for a period of three years from Admission and are exercisable at a price of 1.3 pence per new ordinary share.

**Director/PDMR Shareholdings**

Following completion of the Fundraising, the shareholdings of the Directors and persons closely associated with them who have participated in the Fundraising are set out in the table below:

Name	Number of existing Ordinary Shares	Percentage of existing issued share capital	Number of New Ordinary Shares	Number of Ordinary Shares on Admission	Percentage of enlarged share capital on Admission	Number of Fundraise Warrants
Mark Eccleston	1,976,957	1.49%	20,769,230 <sup>1</sup>	22,746,187	6.08%	20,769,230
Adrian de Courcey	871,036	0.66%	1,538,461	2,409,497	0.64%	1,538,461
Cathy Tralau-Stewart	66,666	0.05%	769,231	835,897	0.22%	769,231
Gerry Desler	195,334	0.15%	769,231	964,565	0.26%	769,231
Martin Gouldstone	0	0.00%	769,231	769,231	0.21%	769,231
<b>Total</b>	<b>3,109,993</b>	<b>2.35%</b>	<b>24,615,384</b>	<b>27,725,377</b>	<b>7.41%</b>	<b>24,615,384</b>

<sup>1</sup>of which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Mr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner. In addition, Mr Eccleston subscribed for a further 3,076,923 New Ordinary Shares as part of the Broker Offer

## Issue of Equity

The Placing Shares, the Subscription Shares and the Broker Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 241,999,999 Placing Shares, Subscription Shares and Broker Offer Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on or around 31 December 2024, with dealings in the Placing Shares, the Subscription Shares and the Broker Offer Shares commencing at the same time. The Placing Shares, the Subscription Shares and the Broker Offer Shares will rank *pari passu* with all other issued Shares.

## Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in the Conditional Fundraising announcement dated 9 December 2024, unless otherwise defined in this announcement.

The Directors of the Company take responsibility for this announcement.

## For further information, please contact:

<b>Investor questions on this announcement</b> We encourage all investors to share questions on this announcement via our investor hub	<a href="https://valirx.com/link/vPn48e">https://valirx.com/link/vPn48e</a>
<b>ValiRx plc</b>  Dr Mark Eccleston, CEO	Tel: +44 (0) 2476 796496 <a href="http://www.valirx.com">www.valirx.com</a> Mark.Eccleston@valirx.com
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b>  Liam Murray / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
<b>Shard Capital Partners LLP (Sole Broker)</b>  Damon Heath	Tel: +44 (0) 20 7186 9000
<b>V Formation (Public Relations)</b>  Lucy Wharton - Senior PR Executive Sue Carr - Director	+44 (0) 115 787 0206 <a href="http://www.vformation.biz">www.vformation.biz</a>  lucy@vformation.biz sue@vformation.biz

## Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

### 1 Details of the person discharging managerial responsibilities/person closely associated

a.	Name	a) Mark Eccleston b) OncoLytika Ltd c) Annette Williams d) Adrian De-Courcey e) Cathy Tralau-Stewart f) Gerrv Desler
----	------	---

		g) Martin Gouldstone																
<b>2 Reason for notification</b>																		
a.	Position/Status	a) Director b) A company which Mark Eccleston has an interest c) PCA of Mark Eccleston d) Director e) Director f) Director g) Director																
b.	Initial notification/ Amendment	Initial notification																
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>																		
a.	Name	ValiRx PLC																
b.	LEI	213800VQKB9SJCQDET40																
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>																		
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary Shares  ISIN: GB00BLH13C52																
b.	Nature of the transaction	Purchase of shares as part of the Fundraising																
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) 0.65p</td> <td>a) 12,923,068</td> </tr> <tr> <td>b) 0.65p</td> <td>b) 5,538,470</td> </tr> <tr> <td>c) 0.65p</td> <td>c) 2,307,692</td> </tr> <tr> <td>d) 0.65p</td> <td>d) 1,538,461</td> </tr> <tr> <td>e) 0.65p</td> <td>e) 769,231</td> </tr> <tr> <td>f) 0.65p</td> <td>f) 769,231</td> </tr> <tr> <td>g) 0.65p</td> <td>g) 769,231</td> </tr> </tbody> </table>	Price(s)	Volume(s)	a) 0.65p	a) 12,923,068	b) 0.65p	b) 5,538,470	c) 0.65p	c) 2,307,692	d) 0.65p	d) 1,538,461	e) 0.65p	e) 769,231	f) 0.65p	f) 769,231	g) 0.65p	g) 769,231
Price(s)	Volume(s)																	
a) 0.65p	a) 12,923,068																	
b) 0.65p	b) 5,538,470																	
c) 0.65p	c) 2,307,692																	
d) 0.65p	d) 1,538,461																	
e) 0.65p	e) 769,231																	
f) 0.65p	f) 769,231																	
g) 0.65p	g) 769,231																	
d.	Aggregated information  - Aggregated Volume  - Price	N/A																
e.	Date of the	30/12/2024																

	transaction	
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	a) Mark Eccleston b) OncoLytika Ltd c) Annette Williams d) Adrian De-Courcey e) Cathy Tralau-Stewart f) Gerry Desler g) Martin Gouldstone				
<b>2 Reason for notification</b>						
a.	Position/Status	a) Director b) A company which Mark Eccleston has an interest c) PCA of Mark Eccleston d) Director e) Director f) Director g) Director				
b.	Initial notification/ Amendment	Initial notification				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	ValiRx PLC				
b.	LEI	213800VQKB9SJCQDET40				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Warrants over Ordinary Shares with an exercise price of 1.3 pence per share and exercisable for a period of three years from Admission.  ISIN: GB00BLH13C52				
b.	Nature of the transaction	Fundraise Warrants received as part of the Fundraising				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
		Price(s)	Volume(s)			

		a) 1.3p b) 1.3p c) 1.3p d) 1.3p e) 1.3p f) 1.3p g) 1.3p	a) 12,923,068 b) 5,538,470 c) 2,307,692 d) 1,538,461 e) 769,231 f) 769,231 g) 769,231
d.	Aggregated information - Aggregated Volume - Price	N/A	
e.	Date of the transaction	30/12/2024	
f.	Place of the transaction	Outside a trading venue	

#### Notes for Editors

##### About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: [www.valirx.com](http://www.valirx.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMKZMFZZGGGDZM